During the past decade, Fondazione IRCCS Istituto Nazionale dei Tumori conducted 340 clinical trials. In the 10-year time frame, 340 clinical trials started and 85 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 148 clinical trials started and 68 clinical trials were completed. i.e. 45.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fondazione IRCCS Istituto Nazionale dei Tumori" #1 sponsor was "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano" with 99 trials, followed by "Italian Sarcoma Group" with 23 trials sponsored, "Celgene" with 17 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 16 trials sponsored and "Hoffmann-La Roche" with 16 trials sponsored. Other sponsors include 304 different institutions and companies that sponsored additional 141 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione IRCCS Istituto Nazionale dei Tumori" #1 collaborator was "Merck Sharp & Dohme LLC" with 15 trials as a collaborator, "AstraZeneca" with 14 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 9 trials as a collaborator, "University of Milan" with 7 trials as a collaborator and "Associazione Italiana per la Ricerca sul Cancro" with 6 trials as a collaborator. Other collaborators include 246 different institutions and companies that were collaborators in the rest 193 trials.

According to Clinical.Site data, the most researched conditions in "Fondazione IRCCS Istituto Nazionale dei Tumori" are "Breast Cancer" (21 trials), "Melanoma" (21 trials), "Ovarian Cancer" (21 trials), "Head and Neck Cancer" (11 trials) and "Multiple Myeloma" (10 trials). Many other conditions were trialed in "Fondazione IRCCS Istituto Nazionale dei Tumori" in a lesser frequency.

Most popular intervention types in "Fondazione IRCCS Istituto Nazionale dei Tumori" are "Drug" (374 trials), "Other" (55 trials), "Procedure" (38 trials), "Biological" (31 trials) and "Radiation" (29 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Pembrolizumab" (22 trials), "Carboplatin" (20 trials), "Paclitaxel" (17 trials) and "Cisplatin" (15 trials). Other intervention names were less common.

The vast majority of trials in "Fondazione IRCCS Istituto Nazionale dei Tumori" are 410 trials for "All" genders, 53 trials for "Female" genders and 17 trials for "Male" genders.

Currently, there are 213 active trials in "Fondazione IRCCS Istituto Nazionale dei Tumori". 1 are not yet recruiting, 108 are recruiting, 103 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 177 completed trials in Fondazione IRCCS Istituto Nazionale dei Tumori, undefined suspended trials, and 33 terminated clinical trials to date.

Out of the total trials that were conducted in Fondazione IRCCS Istituto Nazionale dei Tumori, 66 "Phase 1" clinical trials were conducted, 227 "Phase 2" clinical trials and 142 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 34 trials that are defined as “Not Applicable".

Fondazione IRCCS Istituto Nazionale dei Tumori has several departments that took part in Clinical trials: "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2" - 24 trials, "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1" - 17 trials, "Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B" - 14 trials, "Istituto Nazionale Tumori di Milano; S.C. Oncologia Pediatrica" - 8 trials, "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica" - 7 trials, "S.S. di Oncologia Medica toraco-polmonare - Fondazione IRCCS - Istituto Nazionale Tumori" - 2 trials